Results 1 to 10 of about 7,770 (204)

Financial reimbursement incentives in the use of biosimilars for rheumatoid arthritis in Japan [PDF]

Journal of Pharmaceutical Policy and Practice
Background Biosimilars present a significant opportunity for cost savings. However, the uptake of biosimilars has been inconsistent across different regions and drugs, highlighting the need for effective policy interventions.
Hiroaki Mamiya, Toshiki Fukasawa, Koji Kawakami   +2 more
doaj   +2 more sources

An Overview of Biosimilars—Development, Quality, Regulatory Issues, and Management in Healthcare

Pharmaceuticals
Biological therapies have transformed high-burden treatments. As the patent and exclusivity period for biological medicines draws to a close, there is a possibility for the development and authorization of biosimilars.
Sara Nunes, FRANCISCO Veiga, Sofia Viana   +2 more
exaly   +3 more sources

Biosimilars in rheumatoid arthritis in 2022 – data from the Romanian Registry of Rheumatic Diseases [PDF]

Romanian Journal of Rheumatology, 2023
Objective. The study aimed at determining whether RA patients starting or stopping biosimilars differ in any regard from those starting or stopping originals. Methods.
Horatiu Popoviciu, Florentin Vreju, Claudiu C. Popescu, Corina Mogosan, Elena Rezus, Simona Rednic, Andra Balanescu, Razvan Adrian Ionescu, Catalin Codreanu   +8 more
doaj   +1 more source

Pharmacists' confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study

Exploratory Research in Clinical and Social Pharmacy, 2022
Background: Biosimilars can improve patient access to biological medicines. Although biosimilars have been shown to be equally effective and safe, some patients remain reluctant to transition to biosimilars.
Chiara Gasteiger, Norina Gasteiger, Keith J. Petrie   +2 more
doaj   +1 more source

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2020
Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated.
Mark C. Genovese, Juan Sanchez-Burson, MyungShin Oh, Eva Balazs, Jeffrey Neal, Andrea Everding, Tomas Hala, Rafal Wojciechowski, Gary Fanjiang, Stanley Cohen   +9 more
doaj   +1 more source

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients

Therapeutic Advances in Gastroenterology, 2021
Background: In this analysis we aimed to describe Brazilian inflammatory bowel disease (IBD) patients’ knowledge and perceptions regarding biosimilars and compare with viewpoints from non-Brazilian patients.
Karoline Soares Garcia, Bianca Pocopetz Facas, Marta Brenner Machado, Fábio Vieira Teixeira, Luisa Avedano, Sanna Lönnfors, Rogério Saad Hossne, Laurent Peyrin-Biroulet, Natália Sousa Freitas Queiroz   +8 more
doaj   +1 more source

Biosimilar insulins in international and domestic practice of pharmacist

Фармацевтичний журнал, 2022
In Ukraine, people with diabetes receive insulin, including insulin biosimilars in pharmacies, so pharmacists should increase their knowledge about biosimilar because they become more available in the coming years. The aim of the work was to summarize
I. O. Vlasenko, I. V. Nizhenkovska
doaj   +1 more source

Potential Cost-Savings From the Use of the Biosimilars in Slovakia

Frontiers in Public Health, 2020
Objectives: To analyse the market shares of biosimilars in Slovakia and to calculate the potential cost-savings from the use of biosimilars in Slovakia based on two different data sources.Methods: National reimbursement lists from the Czech Republic ...
Tomas Tesar, Peter Golias, Zuzana Kobliskova, Martin Wawruch, Paweł Kawalec, András Inotai, András Inotai   +6 more
doaj   +1 more source

Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey

Frontiers in Pharmacology, 2022
Objective: With increasing numbers of biosimilars entering the market or in the approval pipeline in China, understanding the current awareness and attitudes of biosimilars still remains the first step to promote uptake.
Yang Hu, Yang Hu, Yang Hu, Yang Hu, Zaiwei Song, Zaiwei Song, Zaiwei Song, Dan Jiang, Dan Jiang, Dan Jiang, Dan Jiang, Lin Zhuo, Yinchu Cheng, Yinchu Cheng, Yinchu Cheng, Rongsheng Zhao, Rongsheng Zhao, Rongsheng Zhao   +17 more
doaj   +1 more source

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019

Pharmaceuticals, 2021
Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System ...
Manuel García-Goñi, Isabel Río-Álvarez, David Carcedo, Alba Villacampa   +3 more
doaj   +1 more source